×
Scilex Holding Total Long Term Liabilities 2021-2024 | SCLX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Scilex Holding total long term liabilities from 2021 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
View More
Scilex Holding Total Long Term Liabilities 2021-2024 | SCLX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Scilex Holding total long term liabilities from 2021 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$173B
Vertex Pharmaceuticals (VRTX)
$129.2B
Bristol Myers Squibb (BMY)
$121.3B
Gilead Sciences (GILD)
$120.8B
CSL (CSLLY)
$91.5B
Regeneron Pharmaceuticals (REGN)
$90.7B
GSK (GSK)
$75.3B
Alnylam Pharmaceuticals (ALNY)
$36.1B
Argenex SE (ARGX)
$35.2B
BioNTech SE (BNTX)
$26.1B
Biogen (BIIB)
$25.1B
Illumina (ILMN)
$24B
BeiGene (BGNE)
$20B
Moderna (MRNA)
$16.5B
Incyte (INCY)
$15.7B
Genmab (GMAB)
$15.4B
Vaxcyte (PCVX)
$12.9B
Insmed (INSM)
$12.8B
BioMarin Pharmaceutical (BMRN)
$12.6B
Bio-Techne Corp (TECH)
$11.9B
Sarepta Therapeutics (SRPT)
$11.3B
Exelixis (EXEL)
$10.3B
Revolution Medicines (RVMD)
$10.2B
QIAGEN (QGEN)
$10.1B
Intra-Cellular Therapies (ITCI)
$9.7B
Exact Sciences (EXAS)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$7.8B
Ascendis Pharma (ASND)
$7.8B